Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies

NCT04172597 is registered in ClinicalTrials.gov with Spectrum Pharmaceuticals, Inc as lead sponsor.

NCT NCT04172597
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04172597 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies
Lead sponsor
Spectrum Pharmaceuticals, Inc
Phase
Phase 2
Overall status
Terminated
Start date
December 23, 2019
Completion date
March 29, 2022
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, glioblastome multiforme, solid tumor